Home > Insider Trading > Filing (0000899243-18-000074)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1674416	Crispr Therapeutics Ag	CRSP	Biological Products, (No Disgnostic Substances) (2836)	473173478

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1682027	Tyler Dylan-Hyde	C/O Crispr Therapeutics Ag Baarerstrasse 14 6300 Zug V8	Chief Legal Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Acquisiton	2017-12-28	700	$14.43	115,904	No	4	M	Direct
Common Shares	Disposition	2017-12-28	700	$21.75	115,204	No	4	S	Direct
Common Shares	Acquisiton	2017-12-29	6,230	$14.43	121,434	No	4	M	Direct
Common Shares	Disposition	2017-12-29	6,230	$21.75	115,204	No	4	S	Direct
Common Shares	Acquisiton	2017-12-29	9,070	$12.57	124,274	No	4	M	Direct
Common Shares	Disposition	2017-12-29	1,070	$21.75	123,204	No	4	S	Direct
Common Shares	Disposition	2017-12-29	8,000	$23.76	115,204	No	4	S	Direct
Common Shares	Disposition	2017-12-29	15,000	$22.68	100,204	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Stock Option (Right to Buy)	Disposition	2017-12-28	700	$0.00	700	$14.43
Common Shares	Stock Option (Right to Buy)	Disposition	2017-12-29	6,230	$0.00	6,230	$14.43
Common Shares	Stock Option (Right to Buy)	Disposition	2017-12-29	9,070	$0.00	9,070	$12.57

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
64,300	2027-06-15	No	4	M	Direct
58,070	2027-06-15	No	4	M	Direct
44,263	2026-07-15	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.7606 to $23.90, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.6771 to $23.00, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
This option was granted on June 15, 2017 with respect to 65,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on July 15, 2017.
This option was granted on July 15, 2016 with respect to 53,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.